Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT05665595 2025-10-15

KEYVIBE-010

Phase 3 Completed

1,594 enrolled 12 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT02752074 2025-08-24

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Phase 3 Completed

706 enrolled 17 charts

Dermatologic

Melanoma

NCT02908672 2025-07-20

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Phase 3 Completed

514 enrolled 25 charts 2 FDA

Dermatologic

Melanoma

NCT01844505 2025-05-21

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Phase 3 Completed

945 enrolled 19 charts

Dermatologic

Melanoma

NCT02166788 2025-05-09

EAGLE FM

Phase 3 Completed

634 enrolled

Dermatologic

Melanoma

NCT03551626 2025-04-29

COMBI-APlus

Phase 3 Completed

552 enrolled 12 charts

Dermatologic

Fever, Melanoma

NCT02388906 2025-04-24

CheckMate 238

Phase 3 Completed

906 enrolled 16 charts 1 FDA

Dermatologic

Melanoma

NCT03635983 2025-04-01

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Phase 3 Completed

783 enrolled 24 charts

Dermatologic

Melanoma

NCT02278887 2025-03-10

TIL

Phase 3 Completed

168 enrolled

Dermatologic

Melanoma

NCT02993315 2025-02-03

MIND-DC

Phase 3 Completed

148 enrolled

Dermatologic

Melanoma

NCT03430297 2024-09-19

JS001

Phase 3 Completed

256 enrolled

Dermatologic

Melanoma

NCT01785316 2024-01-26

SCANDIUM

Phase 3 Completed

93 enrolled

Dermatologic

Melanoma, Uveal Neoplasms

NCT01682083 2023-08-30

COMBI-AD

Phase 3 Completed

870 enrolled 13 charts 1 FDA

Dermatologic

Melanoma, Neoplasms

NCT00003027 2023-06-22

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

Phase 3 Completed

482 enrolled

Dermatologic

Melanoma

NCT00003444 2023-06-22

Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin

Phase 3 Completed

167 enrolled

Dermatologic

Melanoma

NCT01359956 2023-04-11

SICOG 0109

Phase 3 Completed

269 enrolled 12 charts

Dermatologic

Melanoma

NCT03294330 2023-01-12

SPYX

Phase 3 Completed

35 enrolled 9 charts

BreastDermatologic

Breast Neoplasms, Melanoma

NCT02997553 2023-01-09

GASVERT

Phase 3 Completed

744 enrolled

BreastDermatologicGastrointestinalGynecologicHead & Neck

Anus Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT01721772 2022-07-12

CheckMate 066

Phase 3 Completed

418 enrolled 16 charts

Dermatologic

Melanoma

NCT02714218 2022-06-24

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Phase 3 Completed

387 enrolled 28 charts

Dermatologic

Melanoma

NCT01689519 2022-05-02

coBRIM

Phase 3 Completed

495 enrolled 15 charts

Dermatologic

Melanoma

NCT01721746 2022-04-19

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Phase 3 Completed

405 enrolled 16 charts

Dermatologic

Melanoma

NCT03068455 2021-09-20

CheckMate 915

Phase 3 Completed

1,844 enrolled 14 charts

Dermatologic

Melanoma

NCT00324727 2021-06-21

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Phase 3 Completed

93 enrolled

Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT02599402 2021-06-15

CheckMate 401

Phase 3 Completed

533 enrolled 19 charts

Dermatologic

Melanoma

NCT01763164 2021-03-22

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Phase 3 Completed

402 enrolled 21 charts

Dermatologic

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

NCT01584648 2021-02-17

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Phase 3 Completed

423 enrolled 15 charts

Dermatologic

Melanoma

NCT01989572 2020-07-07

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Phase 3 Completed

815 enrolled 10 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT01866319 2020-06-02

MK-3475-006

Phase 3 Completed

834 enrolled 13 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT02545075 2020-05-19

A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine

Phase 3 Completed

182 enrolled 20 charts

Dermatologic

Melanoma

NCT00057616 2019-11-08

Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.

Phase 3 Completed

274 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis

NCT00864253 2019-10-30

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Phase 3 Completed

529 enrolled 22 charts

Dermatologic

Melanoma

NCT01667419 2019-07-23

BRIM8

Phase 3 Completed

498 enrolled 16 charts

Dermatologic

Melanoma

NCT01245062 2018-04-05

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Phase 3 Completed

322 enrolled 24 charts

Dermatologic

Melanoma, Neoplasms

NCT00019682 2017-11-20

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

Phase 3 Completed

185 enrolled 11 charts

Dermatologic

Melanoma

NCT01227889 2017-10-04

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Phase 3 Completed

251 enrolled 21 charts

Dermatologic

Melanoma, Neoplasms

NCT00091572 2017-06-06

Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)

Phase 3 Completed

859 enrolled 11 charts

Dermatologic

Melanoma

NCT00200577 2017-06-01

TIL

Phase 3 Completed

70 enrolled

Dermatologic

Melanoma

NCT00204529 2017-05-03

Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB

Phase 3 Completed

901 enrolled

Dermatologic

Melanoma

NCT01006980 2016-09-28

A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

Phase 3 Completed

675 enrolled 14 charts

Dermatologic

Melanoma

NCT00110019 2015-10-19

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase 3 Completed

823 enrolled 9 charts

Dermatologic

Melanoma

NCT00275496 2015-09-02

Multicenter Selective Lymphadenectomy Trial (MSLT)

Phase 3 Completed

2,001 enrolled

Dermatologic

Melanoma

NCT00006237 2015-03-25

S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma

Phase 3 Completed

432 enrolled 7 charts

Dermatologic

Melanoma

NCT00111007 2014-10-31

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Phase 3 Completed

270 enrolled 15 charts

Dermatologic

Melanoma

NCT00538850 2014-03-05

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Phase 3 Completed

130 enrolled 9 charts

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Breast Carcinoma In Situ, Immunoglobulin Light-chain Amyloidosis, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Anus Neoplasms, Appendiceal Neoplasms, Astrocytoma, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Blast Crisis, Brain Neoplasms, Breast Neoplasms, Burkitt Lymphoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Chondrosarcoma, Colonic Neoplasms, Craniopharyngioma, Vipoma, Ependymoma, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gallbladder Neoplasms, Glioblastoma, Glioma, Glucagonoma, Carcinoma, Hepatocellular, Hodgkin Disease, Immunoblastic Lymphadenopathy, Insulinoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Medulloblastoma, Melanoma, Meningioma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Mycosis Fungoides, Myeloproliferative Disorders, Neoplasms, Oligodendroglioma, Pain, Pancreatic Neoplasms, Penile Neoplasms, Pinealoma, Polycythemia Vera, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Sarcoma, Osteosarcoma, Sezary Syndrome, Somatostatinoma, Stomach Neoplasms, Testicular Neoplasms, Thrombocythemia, Essential, Thymoma, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Gastrinoma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Choroid Plexus Neoplasms, Endometrial Neoplasms, Lymphoma, Large-Cell, Anaplastic, Nephroma, Mesoblastic, Desmoid Tumors, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Esthesioneuroblastoma, Olfactory, Glioma, Subependymal, Gliosarcoma, Lymphoma, B-Cell, Marginal Zone, Breast Neoplasms, Male, Lymphoma, Mantle-Cell, Gastrointestinal Stromal Tumors, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis, Small Cell Lung Carcinoma, Intraocular Lymphoma

Clinical Trials

COLUMBUS

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

LEAP-003

LEAP-003

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

KEYVIBE-010

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

EAGLE FM

COMBI-APlus

CheckMate 238

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

TIL

MIND-DC

JS001

SCANDIUM

COMBI-AD

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin

SICOG 0109

SPYX

GASVERT

CheckMate 066

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

coBRIM

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

CheckMate 915

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

CheckMate 401

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

MK-3475-006

A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine

Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

BRIM8

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)

TIL

Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB

A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Multicenter Selective Lymphadenectomy Trial (MSLT)

S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain